Research: Endo Pharmaceuticals
Pharmaceuticals » Endo Pharmaceuticals
Click here to sign up for a Caris Research Account
1/06/2009
(ENDP) ENDP - Ready, Fire, Aim: Indevus Acquisition Misses The Mark – Downgrading from 2*/Above Average to 3*/Average.
No introduction text is currently available for this report.
1/05/2009
(ENDP) ENDP - Deal or No Deal? Downgrading from 1*/Buy to 2*/Above Average -- Maintain $28 Price Target
No introduction text is currently available for this report.
11/21/2008
(ENDP) ENDP - The Guy with the Cash –Reiterate 1*/Buy and $28 Price Target
No introduction text is currently available for this report.
10/31/2008
(ENDP) ENDP - 3Q EPS Upside Shows Off the GARP – Upgrading to Buy
No introduction text is currently available for this report.
8/21/2008
(ENDP) ENDP - All About Executing on the New Strategy – Initiated with a 2*/Above Average
No introduction text is currently available for this report.
8/20/2008
(ENDP) ENDP - All About Executing on the New Strategy – Initiating with a 2*/Above Average
No introduction text is currently available for this report.
Depending on the investment objectives and financial information specific to your situation, the investments discussed or recommended on this website may or may not be suitable for you. It is your responsibility to consider any investment decision carefully. The information contained on this website should not be construed as advice designed to meet the particular needs of any investor. Past performance is not necessarily indicative of future performance, and does not guarantee future results. The price and/or value of any security noted directly or indirectly on this website may fluctuate adversely to your interests, and/or those of other investors. Caris & Company accepts no liability whatsoever for loss or damage of any sort arising out of use of all or part of any information on this website.